imatinib mesylate has been researched along with Granulomatosis with Polyangiitis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beketova, TV; Naryshkin, EA; Nasonov, EL; Novoselova, TM; Volkov, MY | 1 |
| Birck, R; Hochhaus, A; Kälsch, AI; Schmitt, WH; Soboletzki, M; van der Woude, FJ; Yard, BA | 1 |
1 review(s) available for imatinib mesylate and Granulomatosis with Polyangiitis
| Article | Year |
|---|---|
Imatinib mesylate use in refractory eosinophilic granulomatosis with polyangiitis: a literature review and a case report.
Topics: Adult; Churg-Strauss Syndrome; Female; Glucocorticoids; Granulomatosis with Polyangiitis; Humans; Imatinib Mesylate; Methylprednisolone; Protein Kinase Inhibitors | 2018 |
1 other study(ies) available for imatinib mesylate and Granulomatosis with Polyangiitis
| Article | Year |
|---|---|
Imatinib mesylate, a new kid on the block for the treatment of anti-neutrophil cytoplasmic autoantibodies-associated vasculitis?
Topics: Aged; Antibodies, Antineutrophil Cytoplasmic; Autoimmune Diseases; Benzamides; Cell Proliferation; Cells, Cultured; Culture Media, Conditioned; Cytokines; Drug Evaluation, Preclinical; Endothelium, Vascular; Granulomatosis with Polyangiitis; HLA-DR Antigens; Humans; Imatinib Mesylate; Lymphocyte Activation; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; T-Lymphocytes; Vasculitis | 2008 |